{"id":"W4405897742","doi":"10.1212/wnl.0000000000210268","title":"Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"Neurogenetic and Muscular Disorders Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Ottawa","funders":"Chugai Pharmaceutical; Institut National de la Santé et de la Recherche Médicale; Sarepta Therapeutics; European Commission; Sanofi; PTC Therapeutics; AveXis; Biogen; Amicus Therapeutics; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Pfizer","keywords":"Spinal muscular atrophy; Medicine; Atrophy; Progressive muscular atrophy; Physical medicine and rehabilitation; Pediatrics; Physical therapy; Internal medicine; Amyotrophic lateral sclerosis; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004660253,0.0001839168,0.0005726364,0.0001157969,0.0001234798,0.000349615,0.0002307994,0.0003887463,0.002621134],"category_scores_gemma":[0.0006751817,0.00007177294,0.0004338719,0.0001327916,0.0001987117,0.0002570268,0.0001275118,0.000874874,0.0003352159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004239846,"about_ca_system_score_gemma":0.0005672216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004152439,"about_ca_topic_score_gemma":0.001757441,"domain_scores_codex":[0.9997867,0.00009664919,0.00001582097,0.0000261404,0.0000418247,0.00003285618],"domain_scores_gemma":[0.9996219,0.00009662653,0.0001523838,0.00001339022,0.00003727701,0.00007841759],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1715825,0.007421148,0.04900021,0.006036856,0.001809011,0.00100398,0.0003560884,0.001732317,0.05667439,0.0008544128,0.01765407,0.6858749],"study_design_scores_gemma":[0.1572901,0.421699,0.2911657,0.003519265,0.002759201,0.008891904,0.0008267057,0.005950328,0.03612857,0.001016797,0.0706558,0.00009665026],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9617181,0.02985844,0.0006168206,0.0008144533,0.0001352164,0.0004310877,0.001394613,0.00008140996,0.004949924],"genre_scores_gemma":[0.9889549,0.006908489,0.0008918619,0.000663684,0.0001021403,0.0003256479,0.001148108,0.00001275902,0.0009923843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002621134,"threshold_uncertainty_score":0.008768618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009055922467832234,"score_gpt":0.2718110679125739,"score_spread":0.2627551454447417,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}